Operational Depth
Since its inception, New Rhein has aimed to replicate the operational depth of mid to large-cap pharmaceutical companies in both due diligence and post-investment program management. What began with support from former Novartis colleagues has evolved into a formal bench of over 50 experienced industry executives (EIRs), complemented by the expertise of our investment team and advisory board. This collective insight enables sourcing opportunities, rigorous deal evaluation and high-quality development execution, leading portfolio companies to view New Rhein as a smart, nimble version of a major pharmaceutical partner.
Investment Team
Our investment team has over 100 years of collective experience in sourcing, evaluating, and transacting on novel medical technologies. The team comes from diverse backgrounds, including venture capital, private equity, public equity, investment banking, pharma M&A, clinical development, commercialization, and data science.
Advisory Board
New Rhein’s Advisory Board members bring a wealth of experience to New Rhein. They are well respected senior figures in the Life Sciences Industry snapping Biotech, Big Pharma and Human Capital. They are an important element guiding the strategy of New Rhein.
Executives in Residence (EIR)
Our Executives in Residence (EIR) Program is a key differentiator, providing access to seasoned operators who support deal sourcing, diligence, and can step into technical, C-suite, or board roles. Many are actively involved in our portfolio companies.
